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The last decade has seen the emergence of immunotherapy within oncology. Immune 
checkpoint blockade (ICB), targeting CTLA-4 and the PD-1/PD-L1 axis, is an established 
standard of care in many tumours. Increasingly, combination regimes involving both PD-1 and 
CTLA-4, or combination with other treatment modalities including radiotherapy and 
chemotherapy are being utilised (1). However, immunotherapies have a distinct toxicity, with 
predominantly autoimmune side effects.  
 
The spread of coronavirus disease 2019 (COVID-19) has sparked unprecedented 
international concern (2). But the associated risk of COVID-19 for patients on ICB is unclear. 
This review summarises our preliminary knowledge of the interaction between ICB and 
COVID-19. We discuss the molecular biology of acute respiratory distress syndrome (ARDS), 
and its relationship to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
We speculate on the impact of ICB therapy on this pathological process. We identify further 
issues with ICB in the context of a COVID-19 pandemic. Finally, we recommend a unified 
response to the crisis by British oncologists, under the aegis of the UK Coronavirus Cancer 
Monitoring Project. 
 
Immunology of ARDS and Coronavirus Response 
The deterioration of many patients with COVID-19 is driven by an immune-mediated cytokine 
release syndrome (CRS) and the associated ARDS (3). This is a form of respiratory failure 
characterised by widespread rapid onset inflammation in the lungs. The immunology of ARDS 
is complex. Many of the inflammatory cytokines and chemokines linked to host viral defence 
have also been implicated in the pathogenesis of the syndrome. Higher plasma and alveolar 
concentrations of tumour necrosis factor (TNF)-α, IL-1β, IL-6, and IL-8 have all been linked to 
poorer outcomes (4). Tissue resident macrophages are the likely source of the immune 
response (5), with resultant chemokine secretion leading to tissue ingress of peripheral 
immune cells including neutrophils and lymphocytes (6).   
 
The emerging serological data on SARS-CoV-2 patients resemble this classical ARDS 
picture. Higher levels of IL-2, IL-7, IL-10, granulocyte colony stimulating factor, interferon 
gamma-induced protein 10, monocyte chemoattractant protein-1, macrophage inflammatory 
protein, and TNFα were all seen in patients requiring ITU admission (7). Furthermore, 
analysis of T-cell populations in a case of fatal COVID-19 ARDS revealed an activated CD8+ 
phenotype, with increased granulysin and perforin positivity (8). Elevated IL-6 plasma levels 
have been linked to worse prognosis overall and early phase clinical trials have been 
launched for anti-IL6 drugs tocilizumab (ChiCTR2000029765) (9, 10), siltuximab 
(NCT04322188) and sarilumab (NCT04324073). 
 
ARDS and ICB drugs 
Immune checkpoints have evolved primarily as a mechanism of preventing injury to healthy 
tissue from overzealous immune attack, providing a delicate balance with effective pathogen 
control versus organ collateral damage. Up-regulation of both the PD-1 axis and CTLA-4 is 
seen in response to acute and chronic infections, and the manipulation of checkpoint signalling 
has shown early promise in improving responses to enduring infections including malaria and 
HIV (11).  
 
Whilst an alteration in viral susceptibility with ICB is theoretically possible, our concern is that 
ICB may potentiate ARDS. Indeed, the cytokine profile of ARDS would normally be seen as a 
desirable immune response against tumours (12). Though rare, cases of CRS have been 
reported following anti-PD-1 monotherapy, though are more typical with CAR T-cell therapies. 
These cases are notably felt to be interleukin (IL)-6 driven, responding to the anti-IL-6 drug 
tocilizumab (13). IL-6 plasma levels are unfavourable prognosticators in COVID-19, therefore 
there is potential that ICB may lead to more severe immune hyperactivation or increased 
incidence of ARDS in COVID-19 patients. 
 
Additional problems 
Beyond the worrying link between ARDS and ICB biology, ICB delivery during the COVID-19 
pandemic has three additional problems. 
 
First, the risk of merely attending a hospital environment for therapy delivery.  The nature of 
oncology outpatient clinics has had to change dramatically to minimise the transmission risks 
of busy waiting rooms and multiple healthcare worker interactions (14).  
 
Second is the diagnostic dilemma posed by ICB toxicity. Significant pneumonitis is relatively 
uncommon ICB side effect (Grade 3/4 in 1-2%), although is an important cause of ICB 
treatment-related mortality. However, the radiological features of ICB-related pneumonitis are 
varied and non-pathognomonic, with important differentials including infection and, in the 
current climate, SARS-CoV-2 infection (15). ICB-related pneumonitis might therefore be 
mistaken for COVID-19. 
 
Third are the implications for the management of such pneumonitides, or other immune-
related adverse events (irAEs). The mainstay of therapy is high-dose steroids followed by 
further immunosuppressive agents, including anti-TNFs (15). The use of steroids has been 
controversial so far in the treatment of SARS-CoV-2, with conflicting evidence. At present, the 
World Health Organization (WHO) advises against the administration of steroids to patients 
suspected COVID-19, though there may be a role in critically unwell patients with ARDS, 
however the evidence base for this is beyond the scope of this review. The WHO has also 
recommended against the discontinuation of non-steroidal disease-modifying agents in 
gastroenterological, rheumatological, and dermatological conditions. In conditions where 
steroids are clearly indicated they should continue to be administered (16).  
 
Existing Chinese Epidemiology 
We have a paucity of data to guide the use of ICB therapy during the COVID-19 pandemic.  
Two Chinese reports are welcome but limited in scope. Liang et al. suggested a higher overall 
incidence of COVID-19 in cancer patients (1% vs 0.29% general population), as well as an 
increased severity of infection. However, only 18 cancer patients were included in this study 
and most were cancer survivors in long term follow-up, with no recent systemic anti-cancer 
therapy, with only one patient receiving an unspecified immunotherapy (17). Zhang et al. 
retrospectively analysed a further cohort of 28 SARS-CoV-2-infected cancer patients from 
Wuhan, China. An increased risk of severe infection was once again noted in patients 
receiving systemic therapy in the 14 days prior to presentation, however only one patient had 
received immunotherapy in combination with chemotherapy (18).  
 
The overall number of patients in these studies is small, and resultant analysis is likely to 
remain speculative at this stage. Moreover, we cannot turn to previous coronavirus outbreaks 
to guide us. In 2003, SARS-CoV spread and was contained prior to the development of ICB. 
Likewise, very few patients received ICB treatment during the 2012 Middle East respiratory 
syndrome coronavirus (MERS-CoV) outbreak. Additionally, the scale of the outbreak and 
global impact from both SARS-CoV and MERS-CoV was less severe (19).  
 
The International Oncology Reaction and the UKCCMP 
In the UK, the National Institute for Health and Care Excellence (NICE) has produced a 
guideline for the systemic treatment of cancer patients during the COVID-19 pandemic (14). 
Most of this guideline focuses on pragmatic management strategies that many readers will 
already recognise as happening within their centres, including minimising risk to patients from 
hospital encounters. Treatments should be assigned a priority level, reflecting the overall 
benefit likely from treatment. Immunotherapy treatments are generally likely to be in favourable 
priority groups. NICE has therefore recommended, rather than a total halt to immunotherapy, 
adapted rotas, including reducing the frequency of dosing from every four to six weeks. This 
will help to minimise hospital visits and resource use (14).  
 
Many oncologists are taking a cautious approach, and, where possible, may look to suspend 
immunosuppressive treatment where this is felt safe to do so. This may be secondary to the 
reasonable anxieties outlined above, and to the dearth of specific data. We suggest that 
greater national coordination is required. With concerted evidence gathering, more specific 
clinical guidance could be generated. To this end, the UK Coronavirus Cancer Monitoring 
Project (UKCCMP), launched on 18th March 2020 and is aiming to involve over 90% of UK 
cancer centres. A Local Emergency Response Reporting Group has been created at each UK 
cancer centre to ensure continued updating of the UKCCMP. The project will collect data on 
SARS-CoV-2 positive cancer patients, including present cancer treatment and clinical 
outcomes, enabling oncologists to gain crucial insights to inform decision making with regards 
to immunotherapy (20).  
 
The COVID-19 pandemic continues to evolve and to apply unprecedented pressures to 
healthcare systems globally. There is limited experience of how ICB will alter the clinical 
course of COVID-19 infection, though there are clear mechanistic and biological features 
related to the development of CRS and ARDS that could be deleterious to our patients. An 
urgent contemporaneous collection of real-world oncology COVID-19 patient outcomes is 
urged to allow evidence-based recommendations. 
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